Compare Quest Diagnostics Inc (DGX) vs Honest Company Inc (HNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Honest Company Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Honest Company Inc trades at $5.05 (market cap $533.20M). The key difference: Quest Diagnostics Inc is far larger — about 47.8× Honest Company Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Honest Company Inc for 39 Days on average.
| DGX | HNST | |
|---|---|---|
Market Cap | $25.48B | $533.20M |
Volume | 941,866 | 1,990,155 |
Sector | Health | Consumer Staples |
52-Week High | $247.45 | $5.95 |
52-Week Low | $173.49 | $2.10 |
Typical Hold Time | 56 Days | 39 Days |
Enterprise Value | $31.23B | $436.81M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
HNST trades at $4.99, up 1.22% today, with a bearish technical signal despite recent positive earnings momentum. The company shows mixed fundamentals with revenue of $371.32M in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations with $0.04 EPS, and institutional interest is growing with BlackRock's $25.66M investment in August 2026.
The stock faces headwinds from persistent unprofitability and declining revenue projections for 2026, though strategic exits are improving margins. Analyst consensus is mixed with a $5.30 price target, suggesting limited upside. Key risks include execution on profitability and competitive pressures in personal care markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
